{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:11:01Z","timestamp":1762089061197,"version":"build-2065373602"},"reference-count":15,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the long\u2010term efficacy and safety of erenumab in the subgroup of patients with chronic migraine (CM) in whom prior preventive treatments had failed (TF) (\u22651, \u22652, and \u22653\u00a0TF medication categories) and never failed (preventive na\u00efve or prior preventive treatments had not failed), using the data from a 52\u2010week, open\u2010label treatment period (OLTP) of the parent study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Erenumab is a fully human monoclonal antibody that selectively binds to and inhibits the canonical calcitonin gene\u2010related peptide receptor. There are limited long\u2010term data evaluating the efficacy and safety of erenumab in patients with CM in whom prior preventive treatments had failed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who had completed the 12\u2010week double\u2010blind treatment period (DBTP) in the parent study were eligible to participate in the 52\u2010week OLTP, during which they received erenumab every 4\u00a0weeks. The TF subgroups (\u22651, \u22652, and \u22653\u00a0TF medication categories) were not mutually exclusive; patients in whom prior preventive treatments from \u22653\u00a0medication categories had failed were also counted in the \u22652 and \u22651\u00a0medication categories. Endpoints included monthly migraine days (MMD), monthly acute migraine\u2010specific medication days (MSMD), achievement of \u226550%, \u226575%, and 100% reduction from baseline in MMD, and exposure\u2010adjusted patient incidence rates of adverse events (AEs; per 100 patient\u2010years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Erenumab treatment provided sustained mean reductions in MMD and MSMD relative to the parent study baseline throughout the 52\u00a0weeks of the OLTP across all TF subgroups. At Week 52, the mean MMD change was \u22128.6 (SD 6.6) (baseline: 18.4 [SD 4.5] days) in the \u22651\u00a0TF subgroup. A post hoc completer analysis (52\u00a0weeks [OLTP] erenumab) showed that compared with erenumab 70\u00a0mg, the 140\u00a0mg dose was associated with numerically greater reductions in the mean MMD (Week 40: \u22128.6 and \u22127.2\u00a0days; Week 52: \u22129.7 and \u22127.9\u00a0days [\u22651\u00a0TF subgroup]) and a higher proportion of patients achieved \u226550%, \u226575%, and 100% response thresholds across all subgroups at Weeks 40 and 52. Overall the exposure\u2010adjusted patient incidence rates of AEs did not increase during the OLTP versus the DBTP (\u22651\u00a0TF subgroup: 141.9\/100 versus 317.9\/100 patient\u2010years), and no new safety signals occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The long\u2010term treatment with erenumab was well tolerated and showed sustained efficacy in patients with CM in whom prior preventive treatments had failed, with numerically greater treatment effects for 140\u00a0mg versus 70\u00a0mg.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14313","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T10:51:52Z","timestamp":1653043912000},"page":"624-633","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long\u2010term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis"],"prefix":"10.1111","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0951-5804","authenticated-orcid":false,"given":"Messoud","family":"Ashina","sequence":"first","affiliation":[{"name":"Department of Neurology Danish Headache Center Rigshospitalet Glostrup Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stewart J.","family":"Tepper","sequence":"additional","affiliation":[{"name":"Geisel School of Medicine at Dartmouth  Hanover New Hampshire USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Lewis","family":"Brandes","sequence":"additional","affiliation":[{"name":"Department of Neurology Vanderbilt University School of Medicine Nashville Neuroscience Group  Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[{"name":"Department of Neurology Charit\u00e9 Universit\u00e4tsmedizin  Berlin Germany"},{"name":"Universit\u00e4tsmedizin Greifswald  Greifswald Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy P.","family":"Boudreau","sequence":"additional","affiliation":[{"name":"Centre de Traitement Neurologique  Montreal Qu\u00e9bec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Weatherall","sequence":"additional","affiliation":[{"name":"Department of Neurology Stoke Mandeville Hospital  Aylesbury UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas\u00a0R.","family":"Gantenbein","sequence":"additional","affiliation":[{"name":"Department for Neurology and Neurorehabilitation ZURZACH Care  Bad Zurzach Switzerland"},{"name":"Department of Neurology University Hospital Zurich  Z\u00fcrich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dole\u017eil","sequence":"additional","affiliation":[{"name":"Prague Headache Center DADO MEDICAL sro  Prague Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Klatt","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Wang","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ananda Krishna","family":"Karanam","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Private Limited  Hyderabad India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunfa","family":"Cheng","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel\u00a0D.","family":"Mikol","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-017-0628-6"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416678382"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414547138"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.227793"},{"key":"e_1_2_11_7_1","unstructured":"AimovigTM United States prescribing information. Accessed March 23 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761077s000lbl.pdf"},{"key":"e_1_2_11_8_1","unstructured":"AimovigTMSummary of product characteristics. Accessed March 23 2022.https:\/\/www.ema.europa.eu\/documents\/product\u2010information\/aimovig\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_11_9_1","unstructured":"2018 Novartis marks a new era for migraine patients with the EU approval of Aimovig\u00ae a first\u2010of\u2010its\u2010kind treatment specifically designed for migraine prevention. Press release"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420912726"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418788347"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420973994"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32534-0"},{"issue":"1","key":"e_1_2_11_16_1","first-page":"10","article-title":"Long\u2010term efficacy and safety of erenumab: results from 64 weeks of the LIBERTY study","volume":"39","author":"Reuter U","year":"2019","journal-title":"Cephalalgia"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14313","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14313","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:06:20Z","timestamp":1762088780000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1111\/head.14313"],"URL":"https:\/\/doi.org\/10.1111\/head.14313","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"type":"print","value":"0017-8748"},{"type":"electronic","value":"1526-4610"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"2021-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}